Back to Search Start Over

Circular RNA circCTNNA1 is downregulated in osteoarthritis and sponges miR-29a to suppress LPS-induced apoptosis of synoviocytes.

Authors :
Liu W
Yang H
Feng X
Song J
Zhong W
Source :
Immunopharmacology and immunotoxicology [Immunopharmacol Immunotoxicol] 2022 Feb; Vol. 44 (1), pp. 1-6. Date of Electronic Publication: 2021 Nov 09.
Publication Year :
2022

Abstract

Objective: CircRNA circCTNNA1 has been characterized as a critical player in cancer biology, while its role in other human diseases is unknown. This study was carried out to study the role of circCTNNA1 in osteoarthritis (OA).<br />Materials and Methods: RNA was extracted from synovial fluid samples donated by OA patients ( n  = 62). RT-qPCRs were then performed to determine the expression of circCTNNA1 and miR-29a in these synovial fluid samples. The interaction between circCTNNA1 and miR-29a was predicted using an online program IntaRNA 2.0 and confirmed by RNA pull-down assay. Overexpression of circCTNNA1 and miR-29a was achieved in synoviocytes to analyze their effects on each other's expression. The role of circCTNNA1 and miR-29a in regulating synoviocyte apoptosis was explored by cell apoptosis assay.<br />Results: CircCTNNA1 was downregulated in OA, while miR-29a was overexpressed in OA. CircCTNNA1 and miR-29a were not significantly correlated. RNA pull-down assay illustrated the direct interaction between circCTNNA1 and miR-29a. In synoviocytes, overexpression of circCTNNA1 and miR-29a failed to regulate the expression of each other. CircCTNNA1 overexpression suppressed the enhancing effects of miR-29a overexpression on cell apoptosis induced by LPS.<br />Conclusions: CircCTNNA1 is downregulated in OA, and its overexpression suppresses synoviocyte apoptosis via sponging miR-29a.

Details

Language :
English
ISSN :
1532-2513
Volume :
44
Issue :
1
Database :
MEDLINE
Journal :
Immunopharmacology and immunotoxicology
Publication Type :
Academic Journal
Accession number :
34751080
Full Text :
https://doi.org/10.1080/08923973.2021.1988103